Wolf Greenfield is fortunate to work with clients across industries that are leaders in their fields. To highlight the work they are doing and the ways in which we work together, we feature client spotlights in the form of case studies. In this case study, we profile Embr Labs. Embr Labs was founded by three MIT scientists and is set to carve out a piece of the $10B Digital Therapeutics market through technology that delivers thermal stimulation for therapeutic applications. Today, Embr Labs is the leader in thermal wellness technology. John Harmon has worked with Embr Labs to develop their patent portfolio from the very beginning.
Ed Gates Featured in American Healthcare Leader
In an interview with American Healthcare Leader,Ed Gates shares his journey to becoming an IP lawyer and how Wolf Greenfield has grown since he joined the firm in 1984. Read the full article here.
Wolf Greenfield Recognized by
The Legal 500 in 2020
The firm was listed in the category of "Patents: prosecution (including reexamination and post-grant proceedings)" and was recognized as “one of the most flourishing specialist IP firms in the country.” The Post-Grant Proceedings Practice was acknowledged for achieving “an exceptional success rate for patent owners and petitioners, especially in inter partes reviews.” Read more.
Impact and 'Unintended Benefits' of the Federal Circuit's Suspension of In-Person Oral Arguments
In Law.com, Greg Corbett and Marie McKiernan detail the impact that remote hearings will have on the Federal Circuit.
Wolf Greenfield's Coverage of Booking.com SCOTUS Decision
In IPWatchdog, Amanda Slade and John Strand discuss how the Booking.com Supreme Court ruling marks a key development in the Court’s genericness doctrine. In Managing IP, John was quoted on how the Booking.com case raises survey status. In OneZero, John predicts that the decision may lead to a generic domain trademark registration rush – with few successes.
The Intersection of Regulatory and Patent Exlusivities for the Life Sciences Industry: A Comparative Overview of American and European Schemes
Jonathan Roses and Toby Simpson of Hoffmann Eitle explore regulatory and patent legal differences between the major jurisdictions of the USA and Europe that life sciences companies should be aware of in The Pharma Letter.
Dan Young Quoted by Law360 On the Risks Pandemic Collaborations Pose on Future Patent Disputes
Dan Young discusses the importance of taking a step back to make sure key issues related to intellectual property are being addressed when forming collaborations connected to COVID-19.
